先天性肾性尿崩症(精氨酸加压素抵抗)诊断与管理国际专家共识声明
该共识针对先天性肾性尿崩症(NDI,又称精氨酸加压素抵抗)制定36条推荐,覆盖儿童和成人的诊断、治疗、随访,以及急诊管理、遗传咨询和家庭计划。推荐由欧洲罕见肾病参考网络和欧洲儿童肾脏病学会的儿童与成人肾脏病学、泌尿外科和临床遗传学国际专家及患者倡导者共同制定并分级,经Delphi流程投票专家组验证。共识旨在为照护NDI患者的医疗专业人员及患者家庭提供指导,并强调需进一步研究以支持未来制定循证指南。
要点
- 共识共提出36条推荐,涉及NDI的诊断、治疗、随访、急诊管理、遗传咨询和家庭计划,适用于儿童和成人患者。
- 推荐由欧洲罕见肾病参考网络和欧洲儿童肾脏病学会的儿童与成人肾脏病学、泌尿外科和临床遗传学国际专家及患者倡导者制定并分级。
- 推荐经Delphi流程投票专家组验证,旨在指导照护NDI患者的医疗专业人员及患者家庭。
- NDI由远端肾单位对精氨酸加压素不敏感所致,肾脏失去浓缩尿液能力,导致多尿、多饮和高渗性脱水风险。
- 共识强调需对NDI这一潜在危及生命的疾病不同方面开展进一步研究,以支持未来制定循证指南。
适用人群与场景
- 适用于儿童和成人先天性肾性尿崩症(NDI,精氨酸加压素抵抗)患者。
处置流程与药物剂量
- 共识给出36条推荐,涵盖诊断、治疗、随访、急诊管理、遗传咨询和家庭计划。
红旗征与不能漏的情况
- NDI患者存在高渗性脱水风险。
研究设计与关键结果
- 制定机构为欧洲罕见肾病参考网络和欧洲儿童肾脏病学会,由儿童与成人肾脏病学、泌尿外科和临床遗传学国际专家及患者倡导者制定推荐并分级,经Delphi流程投票专家组验证。
证据类型、等级与局限
- 证据类型:国际专家共识声明。
- 推荐由国际专家组制定并分级,经Delphi流程投票验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识旨在为照护NDI患者的医疗专业人员及患者家庭提供指导。
- 共识强调需进一步研究NDI的不同方面,以支持未来制定循证指南。
指南或共识出处
- 国际专家共识声明:先天性肾性尿崩症(精氨酸加压素抵抗)诊断与管理,发表于Nat Rev Nephrol。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Congenital nephrogenic diabetes insipidus (NDI; also known as arginine vasopressin resistance) is a rare inherited disorder of water homeostasis, caused by insensitivity of the distal nephron to arginine vasopressin. Consequently, the kidney loses its ability to concentrate urine, which leads to polyuria, polydipsia and the risk of hypertonic dehydration. The diagnosis and management of NDI are very challenging and require an integrated, multidisciplinary approach. Here, we present 36 recommendations for diagnosis, treatment and follow-up in both children and adults, as well as emergency management, genetic counselling and family planning, for patients with NDI. These recommendations were formulated and graded by an international group of experts in NDI from paediatric and adult nephrology, urology and clinical genetics from the European Rare Kidney Disease Reference Network and the European Society of Paediatric Nephrology, as well as patient advocates, and were validated by a voting panel in a Delphi process. The goal of these recommendations is to provide guidance to health care professionals who care for patients with NDI and to patients and their families. In addition, we emphasize the need for further research on different aspects of this potentially life-threatening disorder to support the development of evidence-based guidelines in the future.
参考来源
- Levtchenko E, Ariceta G, Arguedas Flores O, et al. International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance). Nat Rev Nephrol. 2024. PMID: 39438674. doi:10.1038/s41581-024-00897-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。